Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 26 (10), 883-92

Pregabalin: In the Treatment of Postherpetic Neuralgia

Affiliations
Review

Pregabalin: In the Treatment of Postherpetic Neuralgia

Kate McKeage et al. Drugs Aging.

Abstract

Pregabalin is the pharmacologically active S-enantiomer of 3-aminomethyl-5-methyl-hexanoic acid. It has a similar pharmacological profile to that of its developmental predecessor gabapentin, but had greater analgesic activity in rodent models of neuropathic pain. Pregabalin is thought to act by reducing the excessive release of several excitatory neurotransmitters by binding to the alpha(2)-delta protein subunit of voltage-gated calcium channels. Oral pregabalin 150-600 mg/day, administered in two or three divided doses, was significantly more effective than placebo in relieving pain and improving pain-related sleep interference in four randomized, double-blind, multicentre studies of 4-13 weeks' duration in patients with postherpetic neuralgia (PHN). Pregabalin achieved a faster onset of pain relief than placebo. The median times to the onset of pain relief with fixed and flexible doses of pregabalin were 1.5 and 3.5 days compared with >4 weeks with placebo. Pregabalin was generally well tolerated when titrated over 1 week to fixed dosages (maximum 600 mg/day) in clinical trials in mostly elderly PHN patients. Adverse events were usually mild to moderate in severity.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

References

    1. Br J Pharmacol. 1997 Aug;121(8):1513-22 - PubMed
    1. Synapse. 2002 Sep 1;45(3):171-90 - PubMed
    1. Expert Opin Investig Drugs. 2003 Apr;12(4):663-72 - PubMed
    1. Pain. 2003 Sep;105(1-2):133-41 - PubMed
    1. Trends Pharmacol Sci. 2007 Feb;28(2):75-82 - PubMed

MeSH terms

Feedback